24 results on '"Su, Yanhong"'
Search Results
2. Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine.
- Author
-
Su, Yanhong, Liu, Bing, Wang, Binghan, Chan, Leung, Xiong, Chan, Lu, Ligong, Zhang, Xuanjun, Zhan, Meixiao, and He, Weiling
- Published
- 2024
- Full Text
- View/download PDF
3. A comparative study of the in vitro antitumor effect of the disulfide-linked and diselenide-linked polyethylene glycol-curcumin nanoparticles.
- Author
-
Zhou, Mengting, Xu, Qingbo, Liu, Jiangfei, Zhu, Tianyu, Su, Yanhong, Chu, Jing, Cao, Huaibao, Hu, Hang, and Xu, Defeng
- Subjects
CURCUMIN ,TURMERIC ,NANOPARTICLES ,POLYETHYLENE ,CYTOTOXINS ,COLLOIDAL stability ,IN vitro studies ,CURCUMINOIDS ,DISULFIDES - Abstract
Curcumin (CUR) is a natural compound extracted from turmeric (Curcuma longa), which has been reported to be a promising anti-cancer drug in various cancers. However, poor water solubility and low bioavailability posed a challenge for clinical application of curcumin. In this work, four CUR prodrugs, namely PEG4000-SS-CUR, PEG1500-SS-CUR, PEG4000-SeSe-CUR and PEG1500-SeSe-CUR were synthesized. These four CUR prodrugs have high CUR loading content and can self-assemble into spherical nanoparticles (NPs) with particle size of 90–190 nm in aqueous solution. The four CUR prodrug NPs exhibit good colloidal stability in PBS buffer and promoted drug release in response to GSH. Due to the enhanced water solubility, the four CUR prodrug NPs all exhibit reduced cellular uptake amount as compared to CUR in in vitro cellular uptake study. The four CUR prodrug NPs exhibit similar cytotoxicity against 22Rv1 cells as compared to free CUR while PEG4000-SeSe-CUR NPs exhibit the highest cytotoxicity and induce the highest cell apoptosis ratio against 4T1 cells in in vitro antitumor effect study. PEG4000-SeSe-CUR NPs developed in this work were proven to be an effective nanoformulation of CUR against 4T1 cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The compensatory role of T cells from lymph nodes in mice with splenectomy.
- Author
-
Liu, Xiaobin, Sun, Yae, Su, Yanhong, Gao, Yang, Zhang, Tianzhe, Wang, Qianhao, Zhang, Xiaoran, Zhang, Dan, Sun, Chenming, Li, Jun, Li, Zongfang, and Zhang, Baojun
- Subjects
T cells ,LYMPH nodes ,CYTOTOXIC T cells ,SPLENECTOMY ,CELL physiology - Abstract
The spleen is a vital organ for the immune system, while splenectomy may be necessary for various reasons. However, there is limited research on the impact of splenectomy on T cell function in peripheral lymph nodes as a compensatory mechanism in preventing infections. This study aimed to investigate the characteristics and function of CD8+ and CD4+ T cells in different peripheral lymph nodes during viral infection using a well‐established splenectomy model. The results revealed that splenectomy caused an increase in CD8+GP33+ T cells in the mesenteric lymph nodes (MLN). Moreover, we demonstrated that splenectomy resulted in an increase of effector KLRG1+ T cells in the MLN. Additionally, the number of CD4+ cytotoxic T cells (CD4 CTLs) was also elevated in the peripheral lymph nodes of mice with splenectomy. Surprisingly, aged mice exhibited a stronger compensatory ability than adult mice, as evidenced by an increase in effector CD8+ T cells in all peripheral lymph nodes. These findings provide compelling evidence that T cells in MLN play a crucial role in protecting individuals with splenectomy against viral infections. The study offers new insights into understanding the changes in the immune system of individuals with splenectomy and highlights the potential compensatory mechanisms involved by T cells in peripheral lymph nodes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Immunogenic PANoptosis‐Initiated Cancer Sono‐Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle.
- Author
-
Zhou, Liqiang, Lyu, Jinxiao, Liu, Fang, Su, Yanhong, Feng, Ling, and Zhang, Xuanjun
- Published
- 2024
- Full Text
- View/download PDF
6. Effects of ultrasound-guided stellate ganglion block on postoperative sore throat and postoperative sleep disturbance after lumbar spine surgery: a randomized controlled trial.
- Author
-
Luo, Decai, Su, Yanhong, and Pang, Yong
- Subjects
LUMBAR vertebrae surgery ,AUTONOMIC ganglia ,SLEEP quality ,GENERAL anesthesia ,NERVE block ,SURGICAL complications ,SLEEP disorders ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,COMPARATIVE studies ,DESCRIPTIVE statistics ,STATISTICAL sampling ,PHARYNGITIS - Abstract
Background: Postoperative sore throat and sleep disturbance are prevalent among patients undergoing spinal surgery, and these conditions can substantially impact their postoperative satisfaction and quality of life. The present study aimed to examine the impact of ultrasound-guided stellate ganglion block (SGB) on the occurrence of postoperative sore throat (POST) and postoperative sleep disturbance (PSD) in patients who undergo lumbar spine surgery under general anesthesia. Methods: Sixty patients were randomly assigned to either the experimental group (SGB group) or the control group (CG). Both groups received the same induction and maintenance drugs. However, the SGB group received a right SGB under ultrasound guidance 15 min before anesthesia induction, while the CG did not receive any block anesthesia intervention before anesthesia induction. We monitored the incidence and severity of POST at 1, 6, 24, and 48 h after surgery in both groups. Additionally, we evaluated the deep sleep quality score on the first, second, and fifth days after surgery in both groups. Results: The incidence of POST at 1 h and 6 h after surgery was significantly lower in the SGB group (10.0% and 13.3%) than in the CG (43.3% and 36.7%) (P < 0.05). The postoperative sore throat scores of the SGB group (0.10 ± 0.31 and 0.17 ± 0.46) at 1 h and 6 h after surgery were lower than those of the CG (0.57 ± 0.73 and 0.50 ± 0.77) (P < 0.05). Moreover, the deep sleep quality score on the first, second, and fifth days after surgery were significantly higher in the CG (5.40 ± 3.37, 4.70 ± 3.19, 4.53 ± 3.44) than in the SGB group (3.87 ± 2.30, 3.13 ± 1.77, 3.03 ± 1.84) (P < 0.05). Conclusion: Ultrasound-guided SGB can reduce the incidence and severity of POST and improve PSD in patients undergoing lumbar spine surgery. Trial registration: This study was registered on Chinese Clinical Trial Registry, (ChiCTR2200065279) on 01/11/2022. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Cuproptosis‐Driven Enhancement of Thermotherapy by Sequentially Response Cu2‐xSe via Copper Chemical Transition.
- Author
-
Chan, Leung, Liu, Yongkang, Chen, Muhe, Su, Yanhong, Guo, Junxian, Zhu, Liwen, Zhan, Meixiao, Chen, Tianfeng, and Lu, Ligong
- Subjects
THERMOTHERAPY ,MALEIC anhydride ,REACTIVE oxygen species ,TUMOR treatment ,TRICARBOXYLIC acids ,SEMIMETALS ,COPPER - Abstract
Activation of cuproptosis pathway has been reported to hold great potential in the application of tumor treatment. But the efficacy of cuproptosis seriously limited by the insufficient accumulation in the tumor sites. Therefore, herein based on the strong stabilization effects of the metalloid element selenium (Se) on copper (Cu), a photothermic Cu2‐xSe nanoparticle encapsulated with bioresponsive dimethyl maleic anhydride (DMMA@Cu2‐xSe) as a copper‐carrier to improve the copper accumulation in tumor is constructed, thus achieving cuproptosis‐driven enhancement of thermotherapy. This nanosystem exhibits the enhancement of tumor cellular uptake by a weak acid‐triggered charge‐switching ability. Next step, the exposed Cu2‐xSe is oxidized and releases divalent copper by high‐level oxide. Then, the abundant copper induces more dihydrolipoamide S‐acetyltransferase oligomerization to down‐regulate FDX1 and tricarboxylic acid cycle‐related proteins, which leads to inhibiting aerobic respiration. Cuproptosis‐induced mitochondrial damage further improves thermotherapy by up‐regulating reactive oxygen species (ROS). In addition, the generated ROS also promotes copper release to strengthen cuproptosis, and eventually improves tumor thermotherapy in turn. In general, DMMA@Cu2‐xSe with sequentially triggered copper‐release, efficient cuproptosis, and appropriate photothermal is a self‐enhanced nanoplatform for cuproptosis‐driven enhancement of thermotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. T cells in health and disease.
- Author
-
Sun, Lina, Su, Yanhong, Jiao, Anjun, Wang, Xin, and Zhang, Baojun
- Published
- 2023
- Full Text
- View/download PDF
9. Amphiphilic Dendrimer Doping Enhanced pH‐Sensitivity of Liposomal Vesicle for Effective Co‐delivery toward Synergistic Ferroptosis–Apoptosis Therapy of Hepatocellular Carcinoma.
- Author
-
Su, Yanhong, Zhang, Zhao, Lee, Leo Tsz On, Peng, Ling, Lu, Ligong, He, Xu, and Zhang, Xuanjun
- Published
- 2023
- Full Text
- View/download PDF
10. Self‐Splittable Transcytosis Nanoraspberry for NIR‐II Photo‐Immunometabolic Cancer Therapy in Deep Tumor Tissue.
- Author
-
Wang, Li, Jiang, Wei, Su, Yanhong, Zhan, Meixiao, Peng, Shaojun, Liu, Hang, and Lu, Ligong
- Subjects
TRANSCYTOSIS ,CANCER treatment ,REGULATORY T cells ,INDOLEAMINE 2,3-dioxygenase ,T cells ,CELL death ,TUMOR growth ,FETAL hemoglobin - Abstract
Cancer photo‐immunotherapy (CPIT) as an ideal strategy can rapidly release hostile signals by appropriate dosage of focal laser irradiation to unmask primary tumor immunogenicity and can activate adaptive immunity to control distant metastases. However, many factors, including disordered immunometabolism, poor penetration of photothermal agents and immuno‐regulators, inadequate laser penetration into the deep tumor region, restrict the therapeutic outcomes of CPIT. Here, a second near‐infrared window (NIR‐II) photo‐immunometabolic cancer therapy (PICT) by a programmed raspberry‐structured nanoadjuvant (PRNMT) is presented that can potentiates efficient immunogenic cell death (ICD) in deep tumor tissue and alleviates immunometabolic disorder. The PRNMT is architected through self‐assembly of indoleamine 2,3‐dioxygenase 1 (IDO‐1) inhibitor modified small‐sized CuS nanoparticles (CuS5) and tumor microenvironment (TME) responsive cationized polymeric matrix. The TME can trigger the splitting and surface cationization of PRNMT into small cationized CuS5 that feature high transcytosis potential and TME immunometabolic regulation. Upon NIR‐II irradiation, CuS5 induce homogeneous ICD and release immunometabolic regulator in deep tumor tissues, which ameliorates IDO‐1 mediated immunometabolic disorder and further suppresses regulatory T cells infiltration. PRNMT mediated PICT effectively delays the primary murine mammary carcinoma 4T1 tumor growth and inhibits the lethal pulmonary metastasis in combination with programmed cell death protein 1 (PD1) blockade. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Security System of Logistics Service Transaction Record Based on Wireless Network.
- Author
-
Su, Yanhong and Yu, Lijing
- Subjects
TRANSACTION records ,ELLIPTIC curve cryptography ,SECURITY systems ,RANDOM forest algorithms ,ELLIPTIC curves ,LOGISTICS - Abstract
Wireless Networks (WNs) and their associated technology paradigms are employed for smart and secure logistics services. The wireless logistics transactions are secured through end-to-end authentication, verification, and third-party watchdog systems. This manuscript introduces a Preemptive Security Scheme for Transaction Verification (PSS-TV) in wireless network-aided logistics services. Different logistics services are secured based on the sender and receiver's signature in mutual consent. Signature generation and implications are varied using the key size and validity based on the previous transaction recommendation. The conventional random forest classifier learning is used for detecting transaction breaches and validity requirements. This is feasible based on the transaction interruptions and failed mutual verifications. These classifications are performed using the learning paradigm for improving the key size in generating stealthy signatures. In the signature generation, the conventional elliptic curve cryptography is relied upon. The proposed scheme's performance is analyzed using success ratio, failure rate, verification and authentication time, and complexity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Pbrm1 intrinsically controls the development and effector differentiation of iNKT cells.
- Author
-
Wang, Xin, Lei, Lei, Su, Yanhong, Liu, Jun, Yuan, Ning, Gao, Yang, Yang, Xiaofeng, Sun, Chenming, Ning, Bin, and Zhang, Baojun
- Subjects
CELL differentiation ,CELL survival ,CELL proliferation ,CELL size ,THYMUS - Abstract
Under static condition, the pool size of peripheral invariant natural killer T (iNKT) cells is determined by their homeostatic proliferation, survival and thymic input. However, the underlying mechanism is not fully understood. In the present study, we found that the percentage and number of iNKT cells were significantly reduced in the spleen, but not in the thymus of mice with deletion of polybromo‐1 (Pbrm1) compared to wild type (WT) mice. Pbrm1 deletion did not affect iNKT cell proliferation and survival, instead significantly impaired their development from stage 1 to stage 2. Importantly, loss of Pbrm1 led to a dysfunction of RORγt expression and iNKT17 cell differentiation, but not iNKT1 and iNKT2 proportion. Collectively, our study reveals a novel mechanism of Pbrm1 controlling the peripheral size of iNKT cells through regulating their development and differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.
- Author
-
Liu, Jun, Zhang, Hui, Su, Yanhong, and Zhang, Baojun
- Subjects
AUTOIMMUNE diseases ,THERAPEUTICS ,PATTERN perception receptors ,B cells ,PORCINE reproductive & respiratory syndrome ,NATURAL immunity ,T cells - Abstract
Dysregulation of auto-reactive T cells and autoantibody-producing B cells and excessive inflammation are responsible for the occurrence and development of autoimmune diseases. The suppression of autoreactive T cell activation and autoantibody production, as well as inhibition of inflammatory cytokine production have been utilized to ameliorate autoimmune disease symptoms. However, the existing treatment strategies are not sufficient to cure autoimmune diseases since patients can quickly suffer a relapse following the end of treatments. Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), Nod-like receptors (NLRs), RIG-I like receptors (RLRs), C-type lectin receptors (CLRs) and various nucleic acid sensors, are expressed in both innate and adaptive immune cells and are involved in the development of autoimmune diseases. Here, we have summarized advances of PRRs signaling pathways, association between PRRs and autoimmune diseases, application of inhibitors targeting PRRs and the corresponding signaling molecules relevant to strategies targeting autoimmune diseases. This review emphasizes the roles of different PRRs in activating both innate and adaptive immunity, which can coordinate to trigger autoimmune responses. The review may also prompt the formulation of novel ideas for developing therapeutic strategies against autoimmune diseases by targeting PRRs-related signals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Arid1a promotes thymocyte development through β‐selection‐dependent and β‐selection‐independent mechanisms.
- Author
-
Yang, Xiaofeng, Wang, Xin, Lei, Lei, Su, Yanhong, Zou, Yujing, Liu, Haiyan, Jiao, Anjun, Zhang, Cangang, Liu, Jun, Li, Wenhua, Ding, Renyi, Zhou, Xiaobo, Shi, Lin, Zhang, Dan, Sun, Chenming, and Zhang, Baojun
- Subjects
CELL death ,T cells ,CELL survival ,CD8 antigen ,CD4 antigen ,THYMUS - Abstract
Early T‐cell development from CD4− CD8− double‐negative (DN) stage to CD4+ CD8+ double‐positive (DP) stage in the thymus is regulated through multiple steps involving a batch of sequentially expressed factors. Our preliminary data and a recent report showed that AT‐rich interaction domain 1A (Arid1a) is required for the transition from DN to DP stages, but the mechanism is not fully understood. In this study, we consolidated that conditional deletion of Arid1a in T‐cell lineage intrinsically caused developmental blocks from DN3 to DN4 stages, as well as from DN4 to DP stages using both in vivo adoptive T‐cell transfer model and in vitro culture system. The expression of intracellular TCRβ is significantly decreased in Arid1a‐deficient DN4 cells compared with WT cells. OT1 transgenic TCR can rescue the defect in the transition from DN3 to DN4 stages, but not from DN to DP stages. Furthermore, we observed a comparable or stronger proliferation capacity accompanied by a significant increase in cell death in Arid1a−/− DP cells compared with that in WT controls. RNA‐Seq analysis shows a significant enrichment of apoptotic pathway within differentially expressed genes between Arid1a−/− and WT DP cells, including the upregulation of Bim, Casp3 and Trp53 and the downregulation of Rorc, Bcl‐XL and Mcl1. Therefore, our study reveals a novel mechanism that Arid1a controls early T‐cell development by maintaining intracellular TCRβ expression‐mediated β‐selection and activating parallel cell survival pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Analysis of the clinical characteristics of insulin autoimmune syndrome induced by alpha‐lipoic acid.
- Author
-
Li, Zuojun, Su, Yanhong, Yi, Dan, Wu, Cuifang, Fang, Weijin, and Wang, Chunjiang
- Subjects
IMMUNOGLOBULINS ,AUTOIMMUNE diseases ,RETROSPECTIVE studies ,INGESTION ,INSULIN ,SYMPTOMS ,LIPOIC acid ,HYPOGLYCEMIA - Abstract
What is known and objective: Alpha‐lipoic acid (ALA) is widely used as a dietary supplement and antiageing agent. Insulin autoimmune syndrome (IAS) is the most serious adverse reaction reported with the use of ALA. The purpose of this study was to explore the clinical characteristics of ALA‐induced IAS and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods: We collected literature on IAS cases induced by ALA for retrospective analysis in Chinese and English. Results and discussion: The median age of 37 patients (28 females and 9 males) was 61 years (range 32–82). The symptoms occurred at night and in the early morning (60.7%), in the late postprandial period (50.0%) or after fasting (35.7%), within hours in some patients and up to 2 months in others after stopping ALA or during medication treatment. Autonomic nervous system symptoms (81.1%) and neurological hypoglycaemia (64.9%) are the main clinical manifestations of hypoglycaemia. The blood glucose concentration at the onset of hypoglycaemia was 2.19 mmol/L (median, range 1.09–3.52), the insulin concentration was ≥100 μIU/ml (94.6%), and the C‐peptide concentration was ≤20 ng/ml (83.3%). Testing for IgG insulin autoantibodies (IAAs) was positive in 37 patients. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and abdominal sonography. Hypoglycaemia disappeared within 5 days to 8 months after withdrawing ALA alone or using corticosteroid treatment. IAA turned negative in 7 months (median; range 2–36). Follow‐up showed no recurrent hypoglycaemic episodes at 7.25 months (median; range 1–36). What is new and conclusion: ALA‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment or after drug withdrawal that should be treated promptly. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Med1 controls CD8 T cell maintenance through IL‐7R‐mediated cell survival signalling.
- Author
-
Lei, Lei, Yang, Xiaofeng, Su, Yanhong, Zheng, Huiqiang, Liu, Jun, Liu, Haiyan, Zou, Yujing, Jiao, Anjun, Wang, Xin, Zhang, Cangang, Zhang, Xingzhe, Zhang, Jiahui, Zhang, Dan, Zhou, Xiaobo, Shi, Lin, Liu, Enqi, Bai, Liang, Sun, Chenming, and Zhang, Baojun
- Subjects
T cells ,CELL communication ,CELL death ,INTERLEUKIN-7 - Abstract
Under steady‐state conditions, the pool size of peripheral CD8+ T cells is maintained through turnover and survival. Beyond TCR and IL‐7R signals, the underlying mechanisms are less well understood. In the present study, we found a significant reduction of CD8+ T cell proportion in spleens but not in thymi of mice with T cell‐specific deletion of Mediator Subunit 1 (Med1). A competitive transfer of wild‐type (WT) and Med1‐deficient CD8+ T cells reproduced the phenotype in the same recipients and confirmed intrinsic role of Med1. Furthermore, we observed a comparable degree of migration and proliferation but a significant increase of cell death in Med1‐deficient CD8+ T cells compared with WT counterparts. Finally, Med1‐deficient CD8+ T cells exhibited a decreased expression of interleukin‐7 receptor α (IL‐7Rα), down‐regulation of phosphorylated‐STAT5 (pSTAT5) and Bim up‐regulation. Collectively, our study reveals a novel role of Med1 in the maintenance of CD8+ T cells through IL‐7Rα/STAT5 pathway‐mediated cell survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Fabrication of thermoresponsive magnetic micelles from amphiphilic poly(phenyl isocyanide) and Fe3O4 nanoparticles for controlled drug release and synergistic thermochemotherapy.
- Author
-
Wang, Qian, Xiao, Jing, Su, Yanhong, Huang, Jianwen, Li, Jihua, Qiu, Lige, Zhan, Meixiao, He, Xu, Yuan, Weizhong, and Li, Yong
- Published
- 2021
- Full Text
- View/download PDF
18. High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.
- Author
-
Su, Yanhong, Zhang, Yarui, Hua, Xin, Huang, Jiajia, Bi, Xiwen, Xia, Wen, Wang, Xinyue, Huang, Zhangzan, Song, Chenge, Zhong, Yongyi, Shi, Yanxia, Wang, Shusen, Fan, Wei, and Yuan, Zhongyu
- Abstract
Background: Tumor progression following endocrine therapy is considered to indicate resistance to endocrine drugs due to a variety of mechanisms. An insufficient dose of endocrine drugs is one of the causes for treatment failure in some patients with high hormone-receptor (HR)-expressing advanced breast cancer. This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR. Materials & methods: This was a single-arm, phase II pilot study that enrolled patients with advanced breast cancer with high HR expression (estrogen receptor ⩾60% and/or progesterone receptor ⩾60%) following routine endocrine therapy. All enrolled patients received a high-dose of TAM (100 mg/day) until disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and safety. Exploratory endpoints included the predictive value of
16 α-18 F-17 β-fluoroestradiol quantitative positron emission tomography/computed tomography (18 F-FES PET/CT) for treatment efficacy. Results: A total of 30 patients were enrolled between September 2017 and February 2019. The median PFS was 6 months [95% confidence interval (CI) 4.9–7.1] and the median OS was 15.6 months (95% CI 8.3–22.9). Five patients experienced a partial response (PR) and none experienced a complete response (CR), with an ORR of 16.7% and CBR of 33.3%. No severe adverse events were observed. Lesions with18 F-FES maximum standardized uptake value (SUVmax) ⩾4 had a significantly longer PFS [median 9.2 months, (95% CI 6.9–11.6)] compared with lesions with a18 F-FES SUVmax <4 [median 4.8 months, (95% CI 3.9–5.6); p = 0.022]. Conclusion: A high-dose of TAM is effective and safe for patients with advanced breast cancer with high HR expression.18 F-FES SUVmax values may predict the local clinical benefits of high-dose TAM. Trial Registration: [ClinicalTrials.gov identifier: NCT0304565] [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.
- Author
-
Su, Yanhong, Zhang, Yarui, Hua, Xin, Huang, Jiajia, Bi, Xiwen, Xia, Wen, Wang, Xinyue, Huang, Zhangzan, Song, Chenge, Zhong, Yongyi, Shi, Yanxia, Wang, Shusen, Fan, Wei, and Yuan, Zhongyu
- Abstract
Background: Tumor progression following endocrine therapy is considered to indicate resistance to endocrine drugs due to a variety of mechanisms. An insufficient dose of endocrine drugs is one of the causes for treatment failure in some patients with high hormone-receptor (HR)-expressing advanced breast cancer. This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR. Materials & methods: This was a single-arm, phase II pilot study that enrolled patients with advanced breast cancer with high HR expression (estrogen receptor ⩾60% and/or progesterone receptor ⩾60%) following routine endocrine therapy. All enrolled patients received a high-dose of TAM (100 mg/day) until disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and safety. Exploratory endpoints included the predictive value of
16 α-18 F-17 β-fluoroestradiol quantitative positron emission tomography/computed tomography (18 F-FES PET/CT) for treatment efficacy. Results: A total of 30 patients were enrolled between September 2017 and February 2019. The median PFS was 6 months [95% confidence interval (CI) 4.9–7.1] and the median OS was 15.6 months (95% CI 8.3–22.9). Five patients experienced a partial response (PR) and none experienced a complete response (CR), with an ORR of 16.7% and CBR of 33.3%. No severe adverse events were observed. Lesions with18 F-FES maximum standardized uptake value (SUVmax) ⩾4 had a significantly longer PFS [median 9.2 months, (95% CI 6.9–11.6)] compared with lesions with a18 F-FES SUVmax <4 [median 4.8 months, (95% CI 3.9–5.6); p = 0.022]. Conclusion: A high-dose of TAM is effective and safe for patients with advanced breast cancer with high HR expression.18 F-FES SUVmax values may predict the local clinical benefits of high-dose TAM. Trial Registration: [ClinicalTrials.gov identifier: NCT0304565] [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer.
- Author
-
Wang, Xinyue, Li, JiBin, Shi, Wei, Huang, Zhangzan, Xia, Wen, Huang, Jiajia, Su, Yanhong, Wang, Shusen, Shi, Yanxia, Bi, Xiwen, and Yuan, Zhongyu
- Subjects
BREAST tumors ,CLINICAL trials ,CONFIDENCE intervals ,METASTASIS ,QUINOLONE antibacterial agents ,SURVIVAL analysis (Biometry) ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,PHARMACODYNAMICS - Abstract
Lessons Learned: Moxifloxacin plus continuation of the previous treatment of physician's choice shows promising efficacy in patients with metastatic breast cancer.The addition of moxifloxacin shows well‐tolerated toxicities. Background: Recent studies have confirmed bacterial infection as an important contributor in cancer. Elimination of tumor‐associated microbes may lead to a reduction in tumors and improved survival. Moxifloxacin is an orally administrated fourth‐generation quinolone with broad‐spectrum coverage against tumor‐associated bacteria. Methods: In this study, we assessed the efficacy and safety of moxifloxacin in combination with treatment of physician's choice (TPC) in patients with metastatic breast cancer (MBC). In this single‐arm, phase II study, we recruited 30 patients with MBC who had a trend toward disease progression (stable disease [SD] with increased tumor size) during TPC before enrollment at Sun Yat‐sen University Cancer Center between January 1 and July 30, 2018. Eligible patients were given moxifloxacin once daily at a dose of 400 mg from days 1 to 7 of a 28‐day cycle, in addition to continuing to receive the therapy previously selected by their physicians. Tumor response was determined according to RECIST (version 1.1). Progression‐free survival (PFS) was calculated using the Kaplan‐Meier method. Results: The concomitant use of moxifloxacin and previous TPC yielded a median PFS of 6.6 months (95% confidence interval [CI]: 4.0–9.1) and a 1‐year PFS of 25.9% (95% CI: 10.0%–41.9%). Objective responses were achieved in seven (23.3%, 95% CI: 7.3%–39.4%) patients. The clinical benefit rate was 46.7% (95% CI: 27.7%–65.6%). No grade 4 adverse events (AEs) and four grade 3 AEs were observed, none of which were considered to have definite relation to moxifloxacin. Conclusion: The combination of moxifloxacin with previous TPC shows promising efficacy and well‐tolerated toxicities in patients with MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
- Author
-
Su, Yanhong, Huang, Jiajia, Wang, Shusen, Unger, Joseph M, Arias-Fuenzalida, Jonathan, Shi, Yanxia, Li, Jibin, Gao, Yongxiang, Shi, Wei, Wang, Xinyue, Peng, Roujun, Xu, Fei, An, Xin, Xue, Cong, Xia, Wen, Hong, Ruoxi, Zhong, Yongyi, Lin, Ying, Huang, Heng, and Zhang, Anqin
- Subjects
CANCER chemotherapy ,BREAST cancer ,NEUROTOXICOLOGY ,MOTOR neuron diseases ,BUPIVACAINE ,ADJUVANT treatment of cancer ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,PERIPHERAL neuropathy ,RESEARCH methodology ,ANTINEOPLASTIC agents ,EVALUATION research ,MEDICAL cooperation ,HYDROCARBONS ,COMPARATIVE studies ,RANDOMIZED controlled trials ,NEUROPROTECTIVE agents ,BREAST tumors ,LIPIDS ,LONGITUDINAL method ,DISEASE complications - Abstract
Background: Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients.Methods: We conducted a randomized, double-blind, placebo-controlled trial including 206 patients with early-stage breast cancer planning to receive taxane-based adjuvant chemotherapy with a follow-up of more than 1 year. Subjects were randomly assigned to receive GM1 (80 mg, day -1 to day 2) or placebo. The primary endpoint was the Functional Assessment of Cancer Treatment Neurotoxicity subscale score after four cycles of chemotherapy. Secondary endpoints included neurotoxicity evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale. All statistical tests were two-sided.Results: In 183 evaluable patients, the GM1 group reported better mean Functional Assessment of Cancer Treatment Neurotoxicity subscale scores than patients in the placebo group after four cycles of chemotherapy (43.27, 95% confidence interval [CI] = 43.05 to 43.49 vs 34.34, 95% CI = 33.78 to 34.89; mean difference = 8.96, 95% CI = 8.38 to 9.54, P < .001). Grade 1 or higher peripheral neurotoxicity in Common Terminology Criteria for Adverse Events v4.0 scale was statistically significantly lower in the GM1 group (14.3% vs 100.0%, P < .001). Additionally, the GM1 group had a statistically significantly lower incidence of grade 1 or higher neurotoxicity assessed by Eastern Cooperative Oncology Group neuropathy scale sensory neuropathy (26.4% vs 97.8%, P < .001) and motor neuropathy subscales (20.9% vs 81.5%, P < .001).Conclusions: The treatment with GM1 resulted in a reduction in the severity and incidence of TIPN after four cycles of taxane-containing chemotherapy in patients with breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling.
- Author
-
Cui, Yanmei, Ma, Weifeng, Lei, Fangyong, Li, Qingyuan, Su, Yanhong, Lin, Xi, Lin, Chuyong, Zhang, Xin, Ye, Liping, Wu, Shu, Li, Jun, Yuan, Zhongyu, and Song, Libing
- Abstract
Breast cancer is the most common malignancy in females. The presence of cancer stem cells ( CSCs) is the main cause of local and distant tumour recurrence and is associated with poor outcome in breast cancer. However, the molecular mechanisms underlying the maintenance of CSCs remain largely unknown. This study demonstrates that prostate tumour overexpressed-1 ( PTOV1) enhances the CSC population and augments the tumourigenicity of breast cancer cells both in vitro and in vivo. Moreover, PTOV1 suppresses transcription of Dickkopf-1 ( DKK1) by recruiting histone deacetylases and subsequently reducing DKK1 promoter histone acetylation, followed by activation of Wnt/β-catenin signalling. Restoration of DKK1 expression in PTOV1-overexpressing cells counteracts the effects of PTOV1 on Wnt/β-catenin activation and the CSC population. Collectively, these results suggest that PTOV1 positively regulates the Wnt/β-catenin signalling pathway and enhances tumourigenicity in breast cancer; this novel mechanism may represent a therapeutic target for breast cancer. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Identification of an RNA-Binding-Protein-Based Prognostic Model for Ewing Sarcoma.
- Author
-
Chen, Yi, Su, Huafang, Su, Yanhong, Zhang, Yifan, Lin, Yingbo, and Haglund, Felix
- Subjects
STATISTICS ,SURVIVAL ,PREDICTIVE tests ,RNA-binding proteins ,IMMUNOHISTOCHEMISTRY ,REGRESSION analysis ,RISK assessment ,GENE expression profiling ,KAPLAN-Meier estimator ,STATISTICAL models ,TUMOR markers ,MOLECULAR structure ,RECEIVER operating characteristic curves ,EWING'S sarcoma - Abstract
Simple Summary: Ewing sarcoma (ES) is an aggressive childhood tumor for which response to chemotherapy is central to long-term prognosis, but few prognostic markers have been identified. RNA-binding proteins (RBPs) are strong regulators of cell behavior, working, for example, through post-translational modifications of mRNA. In this study, we investigated whether patterns in the RBP levels were related to outcomes in ES patients. A total of three distinct patterns were recognized, and additional modelling suggested that 10 RPBs had predictive value, suggesting that this model could be used in a clinical setting to identify patients with a higher risk of mortality. RNA-binding proteins (RBPs) are important transcriptomic regulators and may be important in tumorigenesis. Here, we sought to investigate the clinical impact of RBPs for patients with Ewing sarcoma (ES). ES transcriptome signatures were characterized from four previously published cohorts and grouped into new training and validation cohorts. A total of three distinct subtypes were identified and compared for differences in patient prognosis and RBP signatures. Next, univariate Cox and Lasso regression models were used to identify hub prognosis-related RBPs and construct a prognostic risk model, and prediction capacity was assessed through time-dependent receiver operating characteristics (ROCs), Kaplan–Meier curves, and nomograms. Across the three RBP subtypes, 29 significant prognostic-associated RBP genes were identified, of which 10 were used to build and validate an RBP-associated prognostic risk model (RPRM) that had a stable predictive value and could be considered valuable for clinical risk-stratification of ES. A comparison with immunohistochemistry validation showed a significant association between overall survival and NSUN7 immunoreactivity, which was an independent favorable prognostic marker. The association of RBP signatures with ES clinical prognosis provides a strong rationale for further investigation into RBPs molecular mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma.
- Author
-
Su, Yanhong, Tsagkozis, Panagiotis, Papakonstantinou, Andri, Tobin, Nicholas P., Gultekin, Okan, Malmerfelt, Anna, Ingelshed, Katrine, Neo, Shi Yong, Lundquist, Johanna, Chaabane, Wiem, Nisancioglu, Maya H., Leiss, Lina W., Östman, Arne, Bergh, Jonas, Sedimbi, Saikiran, Lehti, Kaisa, Lundqvist, Andreas, Stragliotto, Christina L., Haglund, Felix, and Ehnman, Monika
- Subjects
SURVIVAL ,PUBLIC health surveillance ,FLOW cytometry ,BIOMARKERS ,ONE-way analysis of variance ,LOG-rank test ,FISHER exact test ,MANN Whitney U Test ,SOFT tissue tumors ,DESCRIPTIVE statistics ,GENE expression profiling ,T cells ,DATA analysis software ,IMMUNOTHERAPY - Abstract
Simple Summary: Immune cells can be powerful regulators of tumor growth and disease progression. Yet, the potential role of professional antigen-presenting cells in soft tissue sarcoma is poorly explored. Both dendritic cells and macrophages may present exogenous antigens through major histocompatibility complex (MHC) class I molecules to CD8+ T cells, a process referred to as cross presentation. With the concept of cellular cross presentation in mind, the present study supports the hypothesis that CD11c+ cells in direct cell-cell contact with CD8+ T cells within the primary tumor are associated with an active anti-tumor immune microenvironment and favorable prognosis. Our work hereby defines a novel biomarker for immune surveillance where presence of spatial cross presentation at tissue level resolution is significantly associated with overall survival. Importantly, this biomarker is independent from established prognostic markers like tumor grade. Biomarkers linked to immune surveillance are expected to gain increasing attention with the advent of immunotherapy in clinical practice. Checkpoint inhibitors are slowly being introduced in the care of specific sarcoma subtypes such as undifferentiated pleomorphic sarcoma, alveolar soft part sarcoma, and angiosarcoma even though formal indication is lacking. Proper biomarkers to unravel potential immune reactivity in the tumor microenvironment are therefore expected to be highly warranted. In this study, intratumoral spatial cross presentation was investigated as a novel concept where immune cell composition in the tumor microenvironment was suggested to act as a proxy for immune surveillance. Double immunohistochemistry revealed a prognostic role of direct spatial interactions between CD11c+ antigen-presenting cells (APCs) and CD8+ cells in contrast to each marker alone in a soft tissue sarcoma (STS) cohort of 177 patients from the Karolinska University Hospital (MFS p = 0.048, OS p = 0.025). The survival benefit was verified in multivariable analysis (MFS p = 0.012, OS p = 0.004). Transcriptomics performed in the TCGA sarcoma cohort confirmed the prognostic value of combining CD11c with CD8 (259 patients, p = 0.005), irrespective of FOXP3 levels and in a CD274 (PD-LI)-rich tumor microenvironment. Altogether, this study presents a histopathological approach to link immune surveillance and patient survival in STS. Notably, spatial cross presentation as a prognostic marker is distinct from therapy response-predictive biomarkers such as immune checkpoint molecules of the PD-L1/PD1 pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.